Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Realm Therapeutics PLC    PURI   GB00B3XBCR18

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/18/2017 07/19/2017 07/20/2017 07/21/2017 07/24/2017 Date
30.75(c) 30.75(c) 30.75(c) 30.75(c) 30.75(c) Last
0 0 0 0 0 Volume
0.00% 0.00% 0.00% 0.00% 0.00% Change
More quotes
Financials ( GBP)
Sales 2017 0,66 M
EBIT 2017 -13,3 M
Net income 2017 -13,1 M
Finance 2017 3,86 M
Yield 2017 -
Sales 2018 5,47 M
EBIT 2018 -13,9 M
Net income 2018 -13,8 M
Finance 2018 2,87 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 17,5x
EV / Sales2018 2,29x
Capitalization 15,4 M
More Financials
Company
Realm Therapeutics Plc is a clinical stage biopharmaceutical company focused on developing novel immunomodulatory therapies.It operates through two segments: Company and Other and Health Science.The Company and Other segment include costs associated with operating Realm Therapeutics plc, and... 
More about the company
Surperformance© ratings of Realm Therapeutics PLC
Trading Rating : - Investor Rating :
More Ratings
Latest news on REALM THERAPEUTICS PLC
07/06 REALM THERAPEUTICS : Presentation at World Congress on Inflammation
03/23 REALM THERAPEUTICS : 2016 Loss Widens As It Progresses Pipeline
02/28 REALM THERAPEUTICS : FDA permits PR022 to Proceed to Phase 2 Trial
02/28 REALM THERAPEUTICS : Phase II Trials Of PR022 Cleared By US FDA
2016 PURICORE : Change of name
2016 PURICORE : Lead Candidates See Progress As It Plans Name Change
2016 PURICORE : Offloads Supermarket Retail Arm, Interim Loss Widens
2016 PURICORE : Granted Two US Patents For Skin Disorder Therapy Production
2016 PURICORE : Strategic Review and Trading Update
2015 PURICORE : Director Dealing
More news
Sector news : Biotechnology & Medical Research - NEC
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
More sector news : Biotechnology & Medical Research - NEC
Chart REALM THERAPEUTICS PLC
Duration : Period :
Realm Therapeutics PLC Technical Analysis Chart | PURI | GB00B3XBCR18 | 4-Traders
Income Statement Evolution
Managers
NameTitle
John Alexander Martin Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Marella Thorell COO, CFO, Secretary & Executive Director
Mark Sampson Vice President-Research & Development
Christian Peters Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
REALM THERAPEUTICS PLC2.50%20
INCYTE CORPORATION33.86%27 485
QUINTILES IMS HOLDINGS INC19.86%19 672
LONZA GROUP31.59%16 914
CELLTRION, INC.--.--%12 564
ALKERMES PLC3.87%8 844